MARKET

AEMD

AEMD

Aethlon Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.710
+0.010
+0.59%
Closed 16:00 05/07 EDT
OPEN
1.690
PREV CLOSE
1.700
HIGH
1.780
LOW
1.675
VOLUME
71.18K
TURNOVER
--
52 WEEK HIGH
3.730
52 WEEK LOW
1.190
MARKET CAP
20.74M
P/E (TTM)
-2.3993
1D
5D
1M
3M
1Y
5Y
Venture Financing - New Trend in the Exosome Diagnostics and Therapeutics Market
May 05, 2021 (MARKITWIRED via COMTEX) -- Future Market Insights in its recent research report titled "Exosome Diagnostic and Therapeutics Market: Global...
Markitwired · 4d ago
Chronic Traumatic Encephalopathy (CTE) Market | 2021 Global Industry Analysis By Size, Growth, Trends, Share, Competitive Landscape, Regional Outlook, Covid-19 Impact With Forecast To 2026
Japan, Japan, Tue, 04 May 2021 06:22:34 / Comserve Inc. / -- Competitive Analysis: Eustralis Pharmaceuticals Ltd, Eli Lilly, Prothena Corp Plc, Amarantus...
Comserve · 5d ago
Exosome Diagnostics and Therapeutics Market Share, Size 2021 Industry Demand, Global Trend, Industry News, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2025
The Express Wire · 04/27 05:48
Exosome Diagnostic and Therapeutics Market 2021:Rapid Growth,Size,Share,Industry Trends,Covid-19 Impact Analysis By Thermo Fisher Scientific, Inc., NanoSomix, Inc., NX PHARMAGEN
Apr 20, 2021 (MARKITWIRED via COMTEX) -- Future Market Insights in its recent research report titled "Exosome Diagnostic and Therapeutics Market: Global...
Markitwired · 04/20 08:18
Exosomes Market COVID-19 Impact and Recovery Analysis (2020-2027)
The Express Wire · 04/20 08:02
Chronic Traumatic Encephalopathy (CTE) Market Dynamics, Share, Size, Growth Factors, Industry Analysis, Report by Top Researcher, Major Challenges, Opportunities and Forecast 2025
The Express Wire · 04/16 07:21
Exosomes Market to Benefit from the Increasing Number of Clinical Trials associated with the Product, says Fortune Business Insights™
Apr 12, 2021 (The Expresswire) -- The global “exosomes” market is projected to witness rapid growth in the coming years driven by the massive investments in...
The Express Wire · 04/12 12:32
Exosome Diagnostic and Therapeutics Market Size 2021: Business Analysis by Top Manufacturers, Latest Technology, Demand Status, Share Estimation, Regional Growth Overview and Forecast to 2025
Apr 07, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The “Exosome Diagnostic and Therapeutics...
The Express Wire · 04/07 10:43
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AEMD. Analyze the recent business situations of Aethlon Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AEMD stock price target is 7.00 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 31
Institutional Holdings: 590.71K
% Owned: 4.87%
Shares Outstanding: 12.13M
TypeInstitutionsShares
Increased
4
99.51K
New
3
32.48K
Decreased
4
68.91K
Sold Out
2
52.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.95%
Healthcare Equipment & Supplies
+0.66%
Key Executives
Chairman/Director
Edward Broenniman
Chief Executive Officer
Charles Fisher
Chief Financial Officer/Senior Vice President - Finance/Secretary/IR Contact Officer
James Frakes
Senior Vice President
Guy Cipriani
Other
Steven Larosa
Independent Director
Sabrina Johnson
Independent Director
Chetan Shah
No Data
  • All
  • Financials
  • Insiders
More
About AEMD
Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.

Webull offers kinds of Aethlon Medical, Inc. stock information, including NASDAQ:AEMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEMD stock methods without spending real money on the virtual paper trading platform.